Skip to main content
Novo NordiskSecurity incident

Novo Nordisk Faces a Three-Part Test: Doctor Data Questions, a Pediatric Insulin Approval and a Buyb

Source: Autobound Signal API · 93 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk suffered a cyberattack that exposed an internal directory classifying healthcare professionals by prescription likelihood and familiarity with its drugs.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Novo Nordisk is under pressure to explain itself on an unusual front. Danish medical and nursing associations are demanding answers about an internal company list that classifies healthcare professionals, according to a report published Friday. The directory became public after a cyberattack, and it sorts clinicians by how likely they are to prescribe Novo Nordisk medicines, along with their familiarity with those drugs. Investors now have a second information file to weigh alongside the drug pipeline. The distinction matters: the cyberattack exposed the list, while the associations' demands concern the list itself. Neither yields a legal verdict on the directory nor an estimate of financial damage. What the dispute does touch is how the company handles data about the people who write its prescriptions - a governance question, not a read on any product's efficacy. On the operational side, the company won FDA approval for Awiqli to improve blood sugar control in children aged ten and older with type 2 diabetes. Novo Nordisk calls it the first once-weekly insulin cleared for this pediatric use. The practical effect is a sharp cut in injection burden: seven basal insulin shots a week become one. That is a regulatory decision, and it stands apart from the clinical-stage work. CagriSema remains an investigational drug, and the data released Tuesday came from post-hoc analyses of...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Security incident

What this signalsA breach often leads to new security spend.

Location
Denmark

More security incident signals at other companies

The full record

From the Signal API record

Details

Issue named
cyberattack exposing an internal company directory classifying healthcare professionals by prescription likelihood and drug familiarity

Extraction

Confidence
85%
Detected
Oct 26, 2026
signal_type
news
signal_subtype
security_incident

Use this data

Get every security incident signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns security incident signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5c2c79b6-c077-5e8d-5621-df057b4b4d21 returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "5c2c79b6-c077-5e8d-5621-df057b4b4d21",
  "signal_type": "news",
  "signal_subtype": "security_incident",
  "detected_at": "2026-10-26T02:10:32+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/novo-nordisk-faces-a-three-part-test-doctor-data-questions-a-pediatric-insulin-approval-and-a/70411515",
    "title": "Novo Nordisk Faces a Three-Part Test: Doctor Data Questions, a Pediatric Insulin Approval and a Buyb - ad-hoc-news.de",
    "excerpt": "Novo Nordisk is under pressure to explain itself on an unusual front. Danish medical and nursing associations are demanding answers about an internal company list that classifies healthcare professionals, according to a report published Friday. The directory became public after a cyberattack, and it sorts clinicians by how likely they are to prescribe Novo Nordisk medicines, along with their familiarity with those drugs. Investors now have a second information file to weigh alongside the drug pipeline. The distinction matters: the cyberattack exposed the list, while the associations' demands concern the list itself. Neither yields a legal verdict on the directory nor an estimate of financial damage. What the dispute does touch is how the company handles data about the people who write its prescriptions - a governance question, not a read on any product's efficacy. On the operational side, the company won FDA approval for Awiqli to improve blood sugar control in children aged ten and older with type 2 diabetes. Novo Nordisk calls it the first once-weekly insulin cleared for this pediatric use. The practical effect is a sharp cut in injection burden: seven basal insulin shots a week become one. That is a regulatory decision, and it stands apart from the clinical-stage work. CagriSema remains an investigational drug, and the data released Tuesday came from post-hoc analyses of...",
    "summary": "Novo Nordisk suffered a cyberattack that exposed an internal directory classifying healthcare professionals by prescription likelihood and familiarity with its drugs.",
    "location": "Denmark",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2671186_1920_1080.webp",
    "confidence": 0.85,
    "published_at": "2026-10-26T02:10:32Z",
    "location_data": [
      {
        "region": "Northern Europe",
        "country": "Denmark",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "vulnerability": "cyberattack exposing an internal company directory classifying healthcare professionals by prescription likelihood and drug familiarity",
    "article_sentence": "The directory became public after a cyberattack, and it sorts clinicians by how likely they are to prescribe Novo Nordisk medicines, along with their familiarity with those drugs."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.